This section of the website is currently under development. This means some parts may not work properly and some documents referred to may not be accessible yet. Please bear with us as we make the website as accessible as possible.
Document library
- APC Position Statement PS-001 Biosimilar Infliximab - September 2015
- APC Position Statement PS-003 Biosimilar Glargine Position - June 2017
- APC Position Statement PS-004 Interim FreeStyle Libre (withdrawn) - November 2018
- APC Position Statement PS-006 Rubefacients UPDATE - February 2020
- APC Position statement PS-007 Lutein Antioxidants - August 2018
- APC Position statement PS-008 Tramadol-paracetamol - August 2018
- APC Position statement PS-009 Dosulepin - August 2018
- APC Position statement PS-010 Trimipramine - August 2018
- APC Position statement PS-012 FreeStyle Libre (withdrawal) - July 2019
- APC Position Statement PS-013 Self Care FINAL - February 2019
- APC Position Statement PS-019 Stoma Adhesives FINAL - July 2019
- APC Position Statement PS-020 Stoma Products FINAL - July 2019
- APC Position Statement PS-021 Liothyronine (GREY) FINAL - February 2020
- APC Position Statement PS-023 Preferred DOACs FINAL - September 2020
- APC Position Statement PS-024 Dronedarone FINAL - March 2020
- APC Position Statement PS-025 Aliskiren (RED) FINAL - July 2020
- APC Position Statement PS-026 Silk Garments (GREY) FINAL - July 2020
- APC Position Statement PS-027 Methylphenidate MR FINAL - September 2020
- APC Postion Statement PS-014 Brand prescribing insulin - March 2019
- APC Postion Statement PS-015 Liothyronine oncology - April 2019
- APC Postion Statement PS-016 Liothyronine depression - April 2019
- APC Postion Statement PS-017 Unlicensed Liothyronine - April 2019
- APC Postion Statement PS-022 Minocycline FINAL - February 2020
- IMOC PS-002 Sativex MS spasticity (AMBER 3) FINAL - April 2022
- IMOC PS-011 Lidocaine plasters (AMBER 2) FINAL – July 2022
- IMOC PS-018 FreeStyle Libre 2 – April 2023
- IMOC PS-028 Methotrexate 10mg tabs (GREY) FINAL - August 2021
- Recommendation 001 Lixisenatide in T2Diabetes
- Recommendation 002 insulin degludec adults (withdrawn) - July 2017
- Recommendation 003 dapagliflozin type 2 diabetes (withdrawn) - November 2016
- Recommendation 004 mirabegron for OAB (withdrawn) - April 2016
- Recommendation 005 Lisdexamfetamine ADHD children - September 2018
- Recommendation 006 Combodart
- Recommendation 007 Linaclotide in IBS - November 2017
- Recommendation 008 Dymista for allergic rhinitis (withdrawn) - June 2017
- Recommendation 009 Lixisenatide in combination with insulin
- Recommendation 010 Ingenol gel (Picato) AK (withdrawn) - January 2020
- Recommendation 011 Relvar Ellipta Astham - COPD (withdrawn) - July 2016
- Recommendation 012 Diltiazem cream for anal fissures
- Recommendation 013 Plenadren® tablets Adrenal insufficiency - September 2014
- Recommendation 014 Levonorgestrel (Jaydess®) Intrauterine Device - September 2014
- Recommendation 015 Aripiprazole depot injection for schizophrenia FINAL
- Recommendation 016 Golimumab in UC (withdrawn) - April 2015
- Recommendation 017 Vedolizumab in Crohns disease (withdrawn) - October 2015
- Recommendation 018 tadalafil post prostatectomy (withdrawn) - May 2017
- Recommendation 019 Vesomni for LUTs (GREY) Final - October 2017
- Recommendation 020 Trospium overactive bladder in children FINAL
- Recommendation 021 Ulipristal pre-op fibroids update - October 2018
- Recommendation 022 Anakinra for acute gout FINAL
- Recommendation 023 Vedolizumab in UC (withdrawn) FINAL - June 2015
- Recommendation 024 Paliperidone Depot Schizophrenia Adults (AMBER) - November 2015
- Recommendation 025 Lurasidone for schizophrenia in adults (AMBER 2) – October 2021
- Recommendation 026 Dapoxetine for premature ejaculation - March 2015
- Recommendation 027 Ketotifen for food allergy - November 2017
- Recommendation 028 Nalcrom food allergy update - June 2017
- Recommendation 029 SURGIFLO® for Intraoperative Bleeding (Neurosurgery) - March 2015
- Recommendation 030 Altoderm™ for mastocytosis in children - April 2015
- Recommendation 031Ropinirole MR Parkinson's Disease - April 2015
- Recommendation 032 Midodrine for IST and POTS (AMBER 3) - January 2018
- Recommendation 033 ivabradine for IST and POTS (AMBER 3) - January 2018
- Recommendation 034 Olopatadine in Seasonal Allergic Conjunctivitis - June 2015
- Recommendation 035 Timolol Eye Gel for Raised Iintraocular Pressure - June 2015
- Recommendation 036 Simbrinza for raised intraocular pressure - June 2015
- Recommendation 037 Octreotide for Chylothorax - August 2015
- Recommendation 038 Ketamine Oral Solution in Palliative Care (RED) - October 2015
- Recommendation 039 Depot Medroxyprogesterone (Sayana Press) Subcut - November 2015
- Recommendation 040 Dexamfetamine Adult ADHD (AMBER 3) - December 2022
- Recommendation 041 Lisdexamfetamine Adult ADHD (AMBER 3) - December 2022
- Recommendation 042 Alteplase for massive sub massive PE (RED) - December 2015
- Recommendation 043 Daily Tadalafil for ED Non-Responsive to PRN (GREY) - December 2015
- Recommendation 044 Duloxetine for Stress Urinary Incontinence - December 2015
- Recommendation 045 Budesonide (Cortiment) for Ulcerative Colitis - December 2015
- Recommendation 046 Methylphenidate Idiopathic hypersomnia - October 2018
- Recommendation 047 dexamfetamine Narcolepsy - October 2018
- Recommendation 048 Tiotropium Respimat in Asthma (AMBER) - March 2016
- Recommendation 049 botulinum toxin hypersalivation (RED) - June 2016
- Recommendation 050 Brivaracetam epilepsy (AMBER) FINAL
- Recommendation 051 Botulinum Toxin in Temporomandibular Jaw - September 2016
- Recommendation 052 Guanfacine ADHD children (AMBER 3) - September 2018
- Recommendation 053 Dulaglutide in Type 2 Diabetes Mellitus (AMBER3) - October 2019
- Recommendation 054 HPV Vaccine Recalcitrant Genital Warts (RED) FINAL - November 2021
- Recommendation 055 Enstilar for psoriasis (GREEN) FINAL – August 2022
- Recommendation 056 Ulipristal Intermitent Treatment Fibroids (RED) FINAL - November 2019
- Recommendation 057 botulinum toxin gastroparesis FINAL - January 2021
- Recommendation 058 Toujeo Type 2 Diabetes update FINAL - January 2021
- Recommendation 059 Insulin degludec (AMBER 2) – February 2023
- Recommendation 060 Gabapentin pregabalin in RLS
- Recommendation 061 Clonazepam in RLS
- Recommendation 062 Opioids in RLS
- Recommendation 063 Pitolisant for narcolepsy (RED) Jan 2021 FINAL - June 2019
- Recommendation 064 Clonidine patches for dystonia - April 2017
- Recommendation 065 Rivaroxaban pelvic fracture - May 2017
- Recommendation 066 anti-MAP for IBD (withdrawn) – February 2023
- Recommendation 067 Dymista for allergic rhinitis - June 2017
- Recommendation 068 Brimonidine gel (Mirvaso) June 2017
- Recommendation 069 Moxifloxacin eye drops - June 2017
- Recommendation 070 botulinum oesophageal spasm (RED) - July 2017
- Recommendation 071 botulinum toxin achalasia (RED) - July 2017
- Recommendation 072 collagenase Peyronies (GREY) - July 2017
- Recommendation 073 Duavive HRT (AMBER2) - August 2017
- Recommendation 074 Tioguanine IBD (RED) - September 2017
- Recommendation 075 Golimumab 100mg IBD - September 2017
- Recommendation 076 Ferric maltol IBD (AMBER2) - February 2023
- Recommendation 077 hyperhidrosis (GREEN) - October 2017
- Recommendation 078 ciclosporin eye VKC AKC children updated - December 2018
- Recommendation 079 Velphoro (RED) FINAL - November 2019
- Recommendation 080 Oestrogen gels in menopause - April 2018
- Recommendation 081 Botulinum anal fissure (RED) - May 2018
- Recommendation 082 Efracea (green) FINAL - May 2018
- Recommendation 083 Ivermectin (green) FINAL - May 2018
- Recommendation 084 Trelegy and Trimbow COPD AMB 1 - June 2018
- Recommendation 085 Spiriva Respimat COPD GREEN - June 2018
- Recommendation 086 Spiolto COPD GREEN - June 2018
- Recommendation 087 Opicapone in Parkinson's Disease - July 2018
- Recommendation 088 Narcolepsy cataplexy - August 2018
- Recommendation 089 Non-REM parasomnia - August 2018
- Recommendation 090 REM Behaviour Disorder (AMBER) - August 2018
- Recommendation 091 REM Behaviour Disorder (RED) - August 2018
- Recommendation 092 Levosert and Kyleena (GREEN) FINAL- March 2022
- Recommendation 093 Desmopressin (Noqdirna) FINAL (RED) - September 2018
- Recommendation 094 Omalizumab inducible urticaria FINAL - December 2018
- Recommendation 095 Zyclara cream for AK (GREY) - January 2019
- Recommendation 096 Aldara cream for BCC (RED) - January 2019
- Recommendation 097 Cariprazine schizophrenia adults (AMBER 2) - February 2022
- Recommendation 098 Aprepitant gastroparesis (RED) - February 2019
- Recommendation 099 Lymecycline rosacea GREEN - March 2019
- Recommendation 100 Etoricoxib AS and RA (AMBER) - April 2019
- Recommendation 101 Buvidal LA injection (RED) - July 2021
- Recommendation 102 Nyxoid intranasal (RED) - July 2021
- Recommendation 103 Mycophenolate Sodium (AMBER 3) FINAL - September 2019
- Recommendation 104 Rivaroxaban SVT (RED) FINAL - June 2019
- Recommendation 105 Testosterone Gel Female libido AMBER2 FINAL – September 2022
- Recommendation 106 Melatonin headache (RED) FINAL - July 2019
- Recommendation 107 Saflutan Taptiqom PF drops AMBER2 FINAL - August 2019
- Recommendation 108 Fixapost IOP AMBER2 FINAL - August 2019
- Recommendation 109 Rivaroxaban HIT (RED) FINAL - October 2019
- Recommendation 110 Glycopyrronium Liquid Hypersalivation AMBER 2 FINAL - September 2019
- Recommendation 111 semaglutide Type 2 diabetes (AMBER 3) FINAL - October 2019
- Recommendation 112 Prasterone pessaries (AMBER 2) December 2021
- Recommendation 113 Actikerall AK (GREEN) FINAL - February 2020
- Recommendation 114 Imiquimod 5 per cent cream AK (GREEN) FINAL - February 2020
- Recommendation 115 Fiasp insulin (AMBER 2) FINAL - February 2020
- Recommendation 116 Safinamide for PD (AMBER 2) – October 2021
- Recommendation 117 Budesonide 3mg AIH (amber 2) FINAL - November 2020
- Recommendation 118 Slenyto paediatrics (amber 3) FINAL - November 2020
- Recommendation 119 Botulinum toxin spasmodic dysphonia (RED) FINAL – April 2022
- Recommendation 120 Invicorp Erectile Dysfunction (Amber 2) FINAL - December 2020
- Recommendation 121 Vitaros Erectile Dysfunction (Amber 2) FINAL - December 2020
- Recommendation 122 rivaroxaban LVT (RED) FINAL - January 2021
- Recommendation 123 Memantine migraine (RED) FINAL - January 2021
- Recommendation 124 ORAL semaglutide Type 2 diabetes (AMBER 3) December 2021
- Recommendation 125 Lenzetto menopause FINAL - April 2021
- Recommendation 126 Pitolisant IH (RED) FINAL – September 2022
- Recommendation 127 Dequalinium for Bacterial Vaginosis (GREEN) – October 2021
- Recommendation 128 Botulinum toxin for neuropathic pain (RED) – October 2021
- Recommendation 129 Botulinum toxin for hand surgery (RED) – October 2021
- Recommendation 130 - Alkindi adrenal insufficiency in paediatrics (AMBER 2) – February 2022
- Recommendation 131 – Xonvea for nausea and vomiting in pregnancy (AMBER 2) – March 2022
- Recommendation 132 – Rivaroxaban for VTE in Paediatrics (RED) – April 2022
- Recommendation 133 – Apixaban for VTE and SSE in HD (RED) – July 2022
- Recommendation 134 Fiasp insulin (AMBER 2) FINAL – August 2022
- Recommendation 135 Dienogest (AMBER 2) FINAL – September 2022
- Recommendation 136 Insulin degludec Paediatrics (AMBER 2) Oct 22 FINAL
- Recommendation 137 Bijuve HRT (GREEN) FINAL – October 2022
- Recommendation 138 Pitolisant for cataplexy (RED) – November 2022
- Recommendation 139 Nystatin for early voice prosthesis failure (AMBER 1) FINAL – December 2022
- Recommendation 140 Rituximab for AIHA (RED) FINAL – December 2022
- Recommendation 141 Jorveza for eosinophilic oesophagitis (AMBER 2) FINAL – March 2023
- Recommendation 142 Treatments for Co-morbid insomnia (AMBER 2) FINAL – April 2023
- Recommendation 143 Treatments for Co-morbid insomnia (RED) FINAL – April 2023